SAT0145 ON TAPERING THERAPY FOR RA PATIENTS IN CLINICAL REMISSION; FLARE ON CS-DMARDS IS PREDICTED BY CLINICAL PARAMETERS AND ULTRASOUND, WHEREAS T-CELL ABNORMALITIES ARE PREDICTIVE FOR B-DMARD TAPERING
Authors: Hanna Gul, Frederique Ponchel, Paul Emery
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background:</h3> Tapering of disease-modifying therapy (DMARDs) is recommended by EULAR/ACR for rheumatoid arthritis (RA) patients who achieve sustained remission on stable therapy(1,2). However, there is no guidance on how to manage this in clinical practice. <h3>Objectives:</h3> We aimed to assess flare over 12 months in RA patients in sustained remission who were offered structured tapering of either conventional synthetic (cs) or biologic (b) DMARDs. <h3>Methods:</h3> RA patients (ACR/EULAR 2010) prospectively attending a remission clinic were recruited when fulfilling the criteria of stable remission as defined by 3-variable DAS28CRP&lt;2.6 for ≥6 months (stable therapy &amp; no corticosteroids). Patients were offered tapering according to a structured protocol (Figure 1). For patients receiving combination cs/b-DMARDs, only the b-DMARD was tapered. Clinical, ultrasound (US) + immunological (T-cell subsets: naïve, Treg (both age-corrected) and inflammation related cells, IRC) data were collected. Flare over a period of 12 months was assessed using several definitions in order to evaluate their relevance for clinical outcomes. Associations with baseline characteristics were assessed using univariate statistics (Mann-Whitney-U and Chi-square). No correction for multiple testing was attempted. <h3>Results:</h3> 98 patients (cs-DMARDs n=66, b-DMARDs n=32) accepted tapering and achieved at least 12 months follow-up. In the cs-DMARD group 55% were female; the median age was 64 years and median remission duration 25 months. For b-DMARDs 63% were female; the median age was 61 years and median remission duration 28 months. There was great heterogeneity in terms of flare rate according to the definitions used (Figure 2). Flare on tapering b-DMARDs was more commonly observed (29-70%) compared to cs-DMARDs (24-52%). Demographics were not associated with flare by any definition (except longer disease duration for cs-DMARD patients who lost Boolean remission status). Clinical (notably seropositivity) and US measures were associated with flare for cs-DMARDs. Reduced Treg and higher IRC's at baseline were associated with flare in patients tapering b-DMARDs. <h3>Conclusion:</h3> Flare rate varied with the definition used and was more common when tapering b-DMARDs compared to cs-DMARDs. Flare was predicted in the latter patients by clinical and US (including seropositivity) findings, whereas T-cell abnormalities predicted flare in b-DMARD patients. These results will help formulate further tapering strategies. <h3>References</h3> [1] Smolen JS, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017. [2] Singh JA, et al. 2015American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis &amp; rheumatology (Hoboken, NJ). 2016. <h3>Disclosure of Interests:</h3> Hanna Gul: None declared, Frederique Ponchel: None declared, Paul Emery Grant/research support from: Pfizer, MSD, AbbVie, Bristol-Myers Squibb, Roche, Consultant for: Pfizer, MSD, AbbVie, Bristol-Myers Squibb, UCB, Roche, Novartis, Gilead,Samsung, Sandoz and Lilly